@theebmt.bsky.social📣 The EBMT Trainee Committee is welcoming new members to join a collaborative team of early-career professionals and young haematologists.
🔎 Learn more about the opportunity to amplify your impact and make sure to apply by 6 November: ebmt.org/ebmt/news/ap...
@sigtrans-sttt.bsky.social
@sigtrans-sttt.bsky.socialCan gingiva-derived MSCs (GMSCs) help preserve β-cell function in #Type1Diabetes (#T1DM)? A phase 1 trial links GMSC therapy to improved residual β-cell function, potentially through CD8+ T-cell exhaustion.
#STTT #OpenAccess: doi.org/10.1038/s413...
#CellTherapy #BetaCellFunction
@drainteo.bsky.socialThankful for the feature in this issue of Stem Cell Reports' "Voices", together with many other eminent stem cell scientists (Shinya, Sonja, Hans, Hongmei, Laurent, Indumathi and Wei) globally.
#stemcells #iPSC #research #celltherapy #imcb #astar #NUS
www.cell.com/stem-cell-re...
@stemcell.comFrequent culture interventions add operational risk to T cell manufacturing. Our low-intervention protocol pairs GMP ImmunoCult™ reagents with G-Rex® Bioreactors for scalable expansion with fewer manipulations.
Read the free protocol: https://bit.ly/4xPPs9D
@hesiglobal.bsky.socialRegister now: NIH and HESI Global hybrid workshop on cell and gene therapies!
View details and register: https://ow.ly/EOnh50ZTTgW
#HESIGlobal #CellTherapy #GeneTherapy #Biodistribution #TranslationalResearch #SafetyScience #collaboration
@longevitytech.bsky.socialThe maker of sasineprocel, a patient-derived cell therapy, has published its preclinical work in *Cell Stem Cell* as it heads toward Phase 3.
Link as first comment.
#longevity #geroscience #sasineprocel #celltherapy #stemcell
@moltherapy.bsky.socialRegistration is now open for the next Molecular Therapy Presents webinar, Beyond prevalence: How rare diseases are shaping therapeutic innovation. Learn more and register here today: http://dlvr.it/TVlH1Z
@jdevos.bsky.socialBlueRock Therapeutics’ #iPSC-derived cell therapy lemiretprocel (OpCT-001) has received orphan drug designation from both the FDA and EMA for inherited retinal diseases.
Now in Phase 1/2a testing for retinitis pigmentosa, Usher syndrome & cone-rod dystrophies. #iPSC #CellTherapy
@ibb-uab.bsky.social📢 There is an open Postdoctoral Position in the Research Group led by Aura Muntasell to work on NK cell immunotherapy for cancer.
📄 All details can be found here: www.uab.cat/en/ibb/doc/2...
Feel free to share! 🧬
#Postdoc #Immunology #CancerResearch #CellTherapy #JobOpportunity
@longevitytech.bsky.socialResolution Therapeutics has treated its last EMERALD trial patient, putting macrophage-based therapy on track for results before year’s end.
Link as first comment.
#longevity #geroscience #macrophage #celltherapy #clinicaltrial
@theebmt.bsky.social🗣️ Present your work at one of the most influential global congresses in HCT, cellular therapy and gene therapy in Rotterdam. #EBMT27
Give your research the chance to gain global recognition and explore available awards, grants, abstract topics, and more ➡️ ebmt.org/annual-meeti...
@ctgct.bsky.socialAt #CaringForRare2026, one message was clear: progress in rare diseases happens when researchers, clinicians and patients work together.
CTGCT's Gregor Cuzak joined discussions to advance gene & cell therapies.
Read more: ctgct.si/en/objave/ct...
@drtimos.bsky.social🧬 Gene & Cell Therapy | #RareDiseases 🚀
#LucidQuest delivers sharp insights to help biotechs, investors & BD teams stay ahead in fast-moving markets.
📩 [email protected] or http://dlvr.it/TVhS2K
#GeneTherapy #CellTherapy #Biotech #DueDiligence #InvestmentInsights
@pharmaphorum.bsky.social#KyvernaTherapeutics has reported new data with its #celltherapy for the rare #autoimmunedisease #stiffpersonsyndrome (SPS), miv-cel, that reinforces its safety as it prepares to complete a rolling FDA filing before the end of this year.
@theebmt.bsky.social🔎 Discover September's Top Picks from Bone Marrow Transplantation, the official journal of EBMT: https://www.ebmt.org/ebmt/news/top-picks-bone-marrow-transplantation-7
@dctomaz.bsky.social🧬 Can engineered Tregs stay stable under inflammation? Deleting a regulatory element near IRF4 helped preserve their suppressive function in preclinical experiments. Patient benefit remains unproven.
doi.org/10.1038/s415...
#Immunology #CellTherapy
@freegardener.bsky.socialRegenerative medicine is shifting from lab curiosity to clinical practice—cell therapy & tissue engineering now #RegenerativeMedicine #CellTherapy #TissueEngineering #Biotech
https://freegardner.com/sci_scout/regenerative-medicine-from-lab-curiosity-to-clinical-practice.html
@aiinmeditech.bsky.socialExplore how CAR-T analytics software , pipeline tracking and competitive intelligence can help biopharma teams understand clinical development, competitors and emerging in-vivo CAR-T opportunities in 2026.
Read: justpaste.it/h5rud
@sigtrans-sttt.bsky.socialResearchers evaluate the novel PARP inhibitor prodrug TSL-1502 in a phase 2 trial, demonstrating promising antitumor activity in BRCA-mutated HER2-negative advanced breast cancer. #ClinicalTrial
#STTT #OpenAccess: doi.org/10.1038/s413...
#CellTherapy #CancerImmunotherapy
